オハイオにおけるバーキットリンパ腫の臨床試験
オハイオ内の拠点で、バーキットリンパ腫に関する17件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他3件
被験者募集中第2相
366 Days – 46 Years · 全性別 · 2026/10/02更新 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Case Western Reserve University, Cleveland
- Cleveland Clinic Foundation, Cleveland
- 他2件
被験者募集中第3相
18歳〜39歳 · 全性別 · 2026/10/02更新 · NCT03150693Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- University of Cincinnati Cancer Center-West Chester, West Chester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他2件
被験者募集中第2相
365 Days · 全性別 · 2026/09/25更新 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
被験者募集中第3相
1歳以上 · 全性別 · 2026/09/17更新 · NCT07223021A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他3件
被験者募集中第2相
1歳〜30歳 · 全性別 · 2026/09/01更新 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他4件
被験者募集中第3相
365 Days – 25 Years · 全性別 · 2026/08/25更新 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
2歳以上 · 全性別 · 2026/05/29更新 · NCT05418088Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Cleveland Clinic Foundation, Cleveland
被験者募集中第2相
18歳〜54歳 · 全性別 · 2026/03/17更新 · NCT06918431Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
1歳〜39歳 · 全性別 · 2026/02/18更新 · NCT06863259Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/05更新 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。